In the November 2020 issue of Movement Disorders, Dommershuijsen and his fellow researchers in the Netherlands wrote an excellent editorial on the ethical considerations of screening for rapid eye movement sleep behavior disorder (RBD) in the healthy general population. I wanted to use this blog to discuss why this question is such an important one to consider as discoveries in the alpha-synucleinopathies continue to advance.
Detecting Alpha-Synuclein in Parkinson’s and Other Synucleinopathies: Proper Pathological Methods Matter
The identification of a reliable biomarker in neurodegenerative diseases such as Parkinson’s disease and Alzheimer’s…
Neurodegenerative diseases like Parkinson’s and dementias continue to represent some of the most significant threats to human health and the healthcare system at large.